Dombeck, Carrie
Swezey, Teresa
Gonzalez Sepulveda, Juan Marcos
Reeve, Bryce B.
LeBlanc, Thomas W.
Chandler, David
Corneli, Amy
Funding for this research was provided by:
Amgen
Article History
Received: 16 August 2022
Accepted: 19 December 2022
First Online: 19 January 2023
Declarations
:
: The Duke University Health System Institutional Review Board (IRB) reviewed and approved the protocol. All participants provided verbal informed consent, which was approved by the Duke University Health System IRB. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable
: TWL reports honoraria for consulting and speaking engagements within the past 24 months from AbbVie, Agios/Servier, Astellas, and BMS/Celgene, as well as honoraria for consulting or advisory board engagements from BlueNote, Flatiron, Genentech, GSK, and Pfizer, as well as research funding from AstraZeneca, BMS, Jazz Pharmaceuticals, and Seattle Genetics, and royalties from UpToDate. D. Chandler was an employee of Amgen during this study. The other authors declare that they have no competing interests.